Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6% – What’s Next?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) traded down 4.6% on Tuesday . The company traded as low as $2.16 and last traded at $2.16. 234,556 shares changed hands during trading, a decline of 78% from the average session volume of 1,070,384 shares. The stock had previously closed at $2.26.

Analysts Set New Price Targets

A number of brokerages have commented on AUTL. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The stock has a 50-day moving average of $2.58 and a 200-day moving average of $3.50. The firm has a market cap of $578.75 million, a price-to-earnings ratio of -1.80 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) EPS. Sell-side analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the 3rd quarter worth $51,000. Dumont & Blake Investment Advisors LLC bought a new position in Autolus Therapeutics during the 4th quarter worth $35,000. Arkadios Wealth Advisors bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at $47,000. Finally, Herbst Group LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter valued at $91,000. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.